Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Troubled Biotechs: Orexigen, Telik, Trubion

This article was originally published in The Pink Sheet Daily

Executive Summary

Vanda’s recent good news gives U.S. biotechs hope for a turnaround, while BIO’s Greenwood predicts most will survive the credit crunch.

You may also be interested in...



Novartis Deal Sealed, Vanda Plays Up Injectable Potential

Vanda turns near-rags to riches selling Fanapt rights back to the originator, a rare feat for a drug in-licensed from Big Pharma.

Novartis Deal Sealed, Vanda Plays Up Injectable Potential

Vanda turns near-rags to riches selling Fanapt rights back to the originator, a rare feat for a drug in-licensed from Big Pharma.

Trubion Finds Kindred Spirit in Facet For Co-Development And Commercialization

Recently launched spinout from PDL BioPharma pays $20 million upfront to Trubion for chronic lymphocytic leukemia candidate.

Related Content

Topics

UsernamePublicRestriction

Register

PS069418

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel